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Abstract
To explore whether antibodies against b2-glycoprotein I (b2GPI) complexed to 7-ketocholesteryl-9-carboxynonanoate
(oxLig-1) and to oxidised low-density lipoproteins (oxLDL) relate to paraoxonase activity (PONa) and/or intima media
thickness (IMT) of carotid arteries in primary antiphospholipid syndrome (PAPS). As many as 29 thrombotic patients with
PAPS, 10 subjects with idiopathic antiphospholipid antibodies (aPL) without thrombosis, 17 thrombotic patients with
inherited thrombophilia and 23 healthy controls were investigated. The following were measured in all participants: b2GPI–
oxLDL complexes, IgG anti-b2GPI–oxLig-1, IgG anti-b2GPI–oxLDL antibodies (ELISA), PONa, (para-nitrophenol
method), IMTof common carotid (CC) artery, carotid bifurcation (B), internal carotid (IC) by high resolution sonography.
b2GPI–oxLDL complex was highest in the control group (p , 0.01), whereas, IgG anti-b2GPI–oxLig1 and IgG anti-
b2GPI–oxLDL were highest in PAPS (p , 0.0001). In healthy controls, b2GPI–oxLDL complexes positively correlated to
IMTof the IC (p ¼ 0.007) and negatively to PONa after correction for age (p , 0.03). PONa inversely correlated with age
(p ¼ 0.008). In PAPS, IgG anti-b2GPI–oxLig-1 independently predicted PONa (p ¼ 0.02) and IMTof B (p ¼ 0.003), CC,
(p ¼ 0.03) and of IC (p ¼ 0.04). In PAPS, PONa inversely correlated to the IMTof B, CC and IC (p ¼ 0.01, 0.02 and 0.003,
respectively). IgG anti-b2GPI–oxLig-1 may be involved in PAPS related atherogenesis via decreased PON activity.
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Introduction
Thrombosis is the main vascular feature of the primary
antiphospholipidsyndrome(PAPS),butsomeevidence
suggeststhatvasculardamageinPAPSmayincludealso
atherosclerosis (Ames et al. 2005). Most of the human
data relating antiphospholipid antibodies (aPL) to
atherosclerosis derive from studies on APS related to
systemic lupus erythematosus, where aPL are variably
associated with greater intima-media thickness (IMT)
and/or focal plaques of carotid arteries although not
predictive of atherosclerosis in regression models
(Manzi et al. 1999, Asanuma et al. 2003, Roman et al.
2003). Nevertheless, mice immunised with aPL and
with b2GPI, the target antigen of aPL, develop
atherosclerosis (George et al. 1998) and aPL titre
independently predicted IMT of carotid arteries,
an acceptable and reliable surrogate marker of
sub-clinical atherosclerosis, in patients with PAPS
(Ames et al. 2002).
Animbalancebetweenoxidativestressandantioxidant
defence contributes to atherogenesis. We previously
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1998) as well as lower antioxidant defence measured as
decreased paraoxonase activity (PONa) in PAPS
(Delgado Alves et al. 2002). PON is the enzyme that
accounts for most of the capacity of high-density
lipoprotein to degrade oxidised phospholipids into
inactive metabolites minimizing the chance of low-
density lipoprotein (LDL) oxidation (Leviev and James
2000). Of further interest is the knowledge that b2GPI
bindstoCu
2þ–oxidisedLDL(oxLDL)(Kobayashietal.
2003) and that macrophages uptake this complex much
faster in the presence of an antibody towards oxLDL–
b2GPI (Hasunuma et al. 1997). More recently, this
concepthasbeenextendedtothecomplexofb2GPIwith
7-ketocholesteryl-9-carboxynonanoate (oxLig-1), the
very oxLDL-derived moiety that binds b2GPI (Liu et al.
2002). As antibodies towards b2GPI–oxLig-1 are
associated with arterial thrombosis in APS (Lopez et al.
2003) we herein explored whether antibodies towards
anti b2G P I – o x L i g - 1b o r ea n ya t h e r o g e n i cp o t e n t i a li n
primary APS.
Methods
Patients
The study populations were drawn from consecutive
patients attending the Coagulation Unit of the
Cardarelli Hospital in Naples (Italy) who gave
informed consent before entering the study, carried
out according to the revised Declaration of Helsinki.
All APS patients met the Sapporo Criteria for PAPS
(Wilson et al. 1999). They were evaluated for a
thrombotic event and were found to be positive for
lupus anticoagulant (LA) and anticardiolipin (aCL)
antibodies on two separate occasions 6 weeks apart.
Patients with idiopathic aPL were detected because
of the presence of a LA on routine clotting screen
for minor surgical procedures or for health checks
and never suffered any vascular manifestation of
APS. Seventeen patients with inherited thrombophi-
lia who underwent vascular occlusions served as a
thrombotic control group. Vascular events were
diagnosed by MRI, doppler ultrasound, ECG and
echocardiogram according to vascular bed involved.
Twenty-three healthy hospital personnel served as a
normal control group. None of the participants were
on lipid lowering agents or antioxidant drugs at the
time of the study. Plasma from patients and controls
were kept at 808C until analysis. Their demo-
graphics and clinical features are presented in
Table I.
Antiphospholipid antibodies
IgG aCL antibodies were measured by ELISA
(Cambridge Life Sciences, UK). A normal range had
been determined from 60 healthy hospital personnel
with a cut-off of 5 GPLU/ml being ﬁve standard errors
above the geometric mean (4.1; SEM 0.2; 95% CI 3.7,
4.5). IgG anti-b2GPI antibodies were measured by
ELISA (Corgenix, Westminster, Co.). As many as 120
serum samples from healthy blood bank donors were
tested for IgG anti-b2GPI antibodies to establish the
cut-off of the assay at 20 units. Intra and inter assay
coefﬁcient of variability was 4.1 and 3%, respectively.
LA was screened by activated partial thromboplastin
time,diluteRusselviper venomtimeandkaolinclotting
time. After detecting an inhibitor bymixing studies, the
plateletneutralisation procedure inthe activated partial
thromboplastintimeanddiluteRusselvipervenomtime
was usedtoconﬁrm the presenceof a LAinaccordance
to published guidelines (Greaves et al. 2000).
Monoclonal antibodies
The following monoclonal antibodies were employed
as described in the assays reported below. WB-CAL-1
is an IgG2a murine monoclonal antibody against
human b2GPI derived from a NZW £ BXSB F1
mouse, a model ofspontaneous APS (Hashimoto et al.
1992). EY2C9 is a human monoclonal IgM anti-
b2GPI antibody established from peripheral blood
lymphocytes of a patient with APS (Ichikawa et al.
1994). These two antibodies bind only to b2GPI-
negatively charged phospholipid (or oxLDL) com-
plexes but not with monomeric (free) b2GPI in
solution. ID2 is a murine IgG monoclonal antibody
speciﬁc for human apolipoprotein B-100 that reacts
equally well with native and oxLDL. IS-4 is another
human monoclonal IgG anticardiolipin established
from peripheral blood lymphocytes of patients with
APS (Zhu et al. 1999).
Measurement of b2GPI–oxLDL complexes
The monoclonal antibody against b2GPI (WB-
CAL-1) was adsorbed on a microtiter plate (Immulon
2HB, Dynex Technology, Inc., Chantilly, VA) by
incubating overnight 50ml/well at a concentration of
50ml/ml dissolved in PBS buffer, pH 7.4, between 2
and 48C. In this assay, WB-CAL-1 captures b2GPI–
oxLDL complexes via its speciﬁcity for b2GPI. The
plate was blocked with PBS-1% skim milk for 1h.
Then, 100ml of samples diluted 1:25 in PBS skim milk
containing 10mmol/l MgCl2 were added to the wells
and incubated for 2h at room temperature. MgCl2
dissociates intermediate b2GPI–oxLDL complexes
bound via electrostatic forces allowing the speciﬁc
detection of non-dissociable and covalently bound
complexespresent in plasma samples (Kobayashiet al.
2003). The wells were washed 4-fold with PBS-0.05%
polysorbate 20 between each step then incubated with
biotinyl-anti-apoB-100-Ab (1D2) diluted in PBS skim
milk for 1h at room temperature. Horseradish
peroxidase streptavidin was added for 30min, colour
was developed with tetramethylbenzidine-H2O2, and
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Optical density was read at 450nm (650nm refer-
ence). The coefﬁcient of variation ranged between 7.2
and 12.3% for weak and 4.5–8.9% for moderate and
strong reactive samples.The concentration of b2GPI–
oxLDL complexes in U/ml was calculated against a
reference curve built with 2-fold serial dilutions of a
b2GPI–oxLDL complex solution. The complexes
were prepared in advance by incubating equal
amounts of Cu
2þ–oxLDL and puriﬁed human
b2GPI, pH 7.4, for 12h at 378C. The unit value
derives arbitrarily from the protein concentration of
the b2GPI–oxLDL used in the reference curve.
A normal cut-off value for the assay was established
testing samples from 100 healthy blood donors
(mean þ 3SD).
Measurement of IgG anti-b2GPI–oxLig-1 antibodies
OxLig-1 (7-ketocholesteryl-9-carboxynonanoate) is a
Cu
2þ-derived LDL ligand for b2GPI prepared as
previously described (Liu et al. 2002). Fifty microliter
of 100mg/ml of oxLig-1 in ethanol were adsorbed by
evaporation on a plain polystyrene plate (Immulon
2HB) followed by blocking with 1% BSA for 1h
at room temperature and then washed. Subsequently,
50mlo f3 0mg/ml of b2GPI in PBS with 3% BSA was
added to oxLig-1-coated wells to allow complex
formation. The b2GPI–oxLig-1 complex represents
the capture antigen for patient antibodies. Finally,
50ml of plasma samples diluted 1:100 in PBS with 3%
BSA were added to the wells and incubated for 1h at
room temperature. Wells were washed four times with
PBS 0.05% polysorbate 20 between steps. Diluted
HRP-conjugated antihuman IgG was added and left
to incubate for 1h. Colour was developed with
tetramethylbenzidine-H2O2, and the reaction stopped
with 0.36N sulphuric acid. Optical density was read at
450nm (650nm reference). The coefﬁcient of
variation ranged between 7.4 and 12.6% for weak
and 5.5–9.9% for moderate and strong reactive
samples. The EY2C9 IgM monoclonal anti-b2GPI
was used in this assay as a reference human antibody
reacting to the b2GPI of the antigenic substrate to
select strong reactive samples to be used as control
samples. However, the IgG b2GPI–oxLig-1 concen-
tration of patient samples (in U/ml) was calculated
against a standard curve prepared from a selected
positive sample. A normal cut-off value for the assay
was established by testing 100 serum samples from
healthy blood donors (mean þ 3SD).
Measurement of IgG anti-b2GPI–oxLDL antibodies
LDL was isolated and oxidised as previously described
(Kobayashi et al. 2003). OxLDL (50mg/ml in ethanol,
50ml well) was adsorbed by evaporation on plain
polystyrene plates (Immulon 1B) and the plates
blocked with 1% BSA. Serum samples (diluted
1:100) were incubated in the wells with or without
b2GPI (25mg/ml) for 1h followed by the addition of
HRP-labelled antihuman IgG. Further steps were
performed as in ELISA for anti-b2GPI–oxLig-1. The
mean OD of the blank wells was employed to correct
Table I. Demographics and clinical features of the study populations.
CTR THR CTR APL PAPS
n 23 17 10 29
Female/male 13/7 11/6 7/3 20/9
Age (median, range) 35 (20–68) 40 (30–58) 40 (29–54) 38 (27–63)
IgG aCL (median, range) 59 (16–309) 118 (24–573)
IgG anti-b2GPI 147 (40–216) 183 (1–226)
FVL 0 12 0 2
PT 20210 1 2 1 1
PC deﬁciency 0 3 0 0
IS 28
MI 01
DVT 11 15
PE 45
Smoking 3 4 2 5
Hypertension 0 0 0 1
Diabetes 0 0 0 1
Obesity 0 0 0 0
High cholesterol 0 0 0 1
High triglycerides 0 0 1 2
Aspirin (75mg) 0 1 6 0
Warfarin 0 17 0 29
CTR: controls; THR CTR: thrombotic controls; APL: antiphospholipid antibodies positive without thrombosis and underlying disorder;
PAPS: primary antiphospholipid syndrome; FVL: factor V Leiden; PT: prothrombin 20210; PC: protein C; IS: ischaemic stroke; MI:
myocardial infarction; DVT: deep vein thrombosis; PE: pulmonary embolism.
Primary antiphospholipid syndrome 3the raw OD of individual samples. OD variation
among plates was normalised using a positive control.
A sample was considered to be positive when its
antibody titre was higher than three standard
deviations above the mean OD of plasma samples
from 150 normal subjects (blood donors).
Paraoxonase activity
Serum PON activity was measured as previously
described (Delgado Alves et al. 2002). Brieﬂy, PON
(1.0mM) freshly prepared in 300ml of 50mM glycine
buffer containing 1mM calcium chloride (pH 10.5)
was incubated at 378C with 5ml of serum for 15min in
96 well plates (Polysorp, Nunc, Life Technologies,
Paisley, UK). Para-nitrophenol formation was mon-
itored at 412nm and activity expressed as nmol of
para-nitrophenol per ml serum per minute. For
graphical purposes baseline PONa activity was set at
100% with percentage decrements thereafter.
Effect of monoclonal antiphospholipid antibodies
on paraoxonase activity
The possible inhibitory effect of aPL on PON activity
was explored. Dose dependency was performed by
incubating doubling dilutions (2, 4, 8 and 16 fold) of
IS4 supernatant (starting at 10g/ml, the maximum
supernatant concentration), WB-CAL-1 and EY2C9
with 50ml of pooled sera from ﬁvehealthy subjects as a
source of PON. PON activity was then measured
every 30min for 4.5h, because speciﬁc paraoxon
hydrolysis starts at about 2h from its incubation
with PON. As controls we used irrelevant human
IgG (Sigma-Aldrich, Poole, UK) at the same
concentration. The possible effect of b2GPI and
b2GPI–oxLDL on PON was also investigated.
All experiments were run in triplicate.
Carotid intima-media thickness measurement
All participants underwent a detailed ultrasound
evaluation of the carotid arteries performed by an
experienced angiologist (AM), using an Aloka 2000
sonograph equipped with a 5–10MHz linear transdu-
cer. The image acquisition followed the Atherosclero-
sis Risk in Communities Study protocol (Heiss et al.
1991). Images were obtained with the patient in the
supine position with the neck slightly extended.
Transverse and longitudinal views of the right and
leftcommoncarotid(CC)arteries(10mmdistaltothe
carotid bifurcation), right and left carotid bifurcation
(B) and internal carotid (IC) arteries were taken. The
means of three measurements taken 1cm apart at the
three different sites were computed for each region,
right and left measurements were averaged for the
purpose of statistical analysis. Plaques, deﬁned as the
presence of focal, severe wall thickening
(IMT . 2mm), wall irregularities and calciﬁcation,
were also looked for. Intra-reader reproducibility was
assessed in two ways. Firstly, the same carotid
measurement was performed twice on 20 individuals
yielding a coefﬁcient of agreement of 97%. Secondly,
the same IMT measurements were performed six
times on one individual over a two-month period,
yielding a coefﬁcient of variability between 3 and 4%
according to carotid segment under study.
Statistics
Non-parametric tests were employed throughout
because of the small numbers in groups. Comparisons
across groups were assessed by Kruskall–Wallis
analysis of variance with Dunns post hoc as appro-
priate. Univariaterelationships betweenvariableswere
examined by Spearman rank and implemented where
described by multiple regression analysis.
Results
PON activity, b2GPI–oxLDL complexes, anti-b2GPI–
oxLDL and anti-b2GPI–oxLig-1 in study groups
PON activity (nmol/ml/min) was not different across
the groups, being 0.96 ^ 0.25 in normal controls,
0.90 ^ 0.340 in thrombotic controls, 0.87 ^ 0.40 in
idiopathic aPL and 78 ^ 0.35 in APS patients. Plasma
levels of b2GPI–oxLDL complexes were highest in
the control group (Figure 1A), whereas, those of IgG
anti-b2GPI–oxLDL (Figure 1B) and anti-b2GPI–
oxLig-1 (Figure 1C) were highest in the APS and aPL
groups. These variables showed no gender differences
in any of the groups, and no differences were noted
between patients with arterial or venous thrombosis in
the PAPS group.
Relationship amongst variables in the normal control group
Several variables in this group were age related: PONa
(Figure (2A)), b2GPI–oxLDL complexes (r ¼ 0.61,
p ¼ 0.001) IgG anti-b2GPI–oxLig-1 (r ¼ 0.46,
p ¼ 0.02) and IMT of all carotid segments
(p ¼ 0.0001). b2GPI–oxLDL negatively correlated
to PONa (Figure 2B), positively to the IMTof the IC
artery (Figure 2C) and to IgG anti-b2GPI–oxLig-1
(r ¼ 0.51, p ¼ 0.01). After correction for age, b2GPI–
oxLDL maintained its correlation with PONa only
(r ¼ 20.46, p ¼ 0.03).
Relationship amongst variables in the thrombotic control
group
b2GPI–oxLDL complexes correlated to the IMT of
the common (r ¼ 0.54, p ¼ 0.02) and the IC artery
(r ¼ 0.53, p ¼ 0.03) and negatively to PONa
(r ¼ 20.51, p ¼ 0.03). Only a trend was seen with
age (r ¼ 0.47, p ¼ 0.07), IMTof all carotid segments
strongly correlated to age (p ¼ 0.0001).
P. R. J. Ames et al. 4Figure 1. Median plasma levels of b2GPI–oxLDL (A), of IgG anti-b2GPI–oxLDL (B) and of anti-b2GPI–oxLig-1 (C) in the four study
groups. CTR: normal controls; THR CTR; thrombotic controls; aPL: non-thrombotic idiopathic antiphospholipid antibody subjects; APS:
thrombotic primary antiphospholipid antibody syndrome patients.
Figure2. Relationship betweenPONactivityandage(A),and betweenb2GPI–oxLDLandPONa(B) andIMT(C)of ICarteriesin normal
controls.
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IgG anti-b2GPI–oxLig-1 correlated to the IMTof the
B( r ¼ 0.8, p ¼ 0.002) and a trend was noted for the
CC (r ¼ 0.52, p ¼ 0.08). No other correlations were
noted because of the limited size of this group.
Relationship amongst variables in the APS group
Because two patients in this group did not have all
variables measured, resulting analysis and data refer to
28patients.WithregardstoantibodysubtypesIgGanti-
b2GPI–oxLig-1positivelycorrelatedtoIgGanti-b2GPI
(r ¼ 0.49, p ¼ 0.007) and to IgG aCL (r ¼ 0.61,
p ¼ 0.0005). In decreasing order of strength PONa
inversely correlated to IgG anti-b2GPI–oxLig-1
(r ¼ 20.51, p ¼ 0.004), to IgG aCL (r ¼ 20.53,
p ¼ 0.003) and to IgG anti-b2GPI (r ¼ 20.41,
p ¼ 0.02). Of these, only IgG anti-b2GPI–oxLig-1
independently predictedPONa(b ¼ 0.44, p ¼ 0.02) in
amultipleregressionthattook intoaccount the effectof
age and sex. In addition, PONa inversely correlated to
theIMToftheIC(Figure3A)andoftheB(Figure3B).
IgG anti-b2GPI–oxLig-1 positively correlated to IMT
of all carotid segments (Figure 4A–C). In a multiple
regressionmodelthatincludedIgGanti-b2GPI–oxLig-
1, IgG anti-b2GPI, and IgG anti-b2GPI–oxLDL as
independentvariablesandIMTasadependentvariable,
and after correction for age and sex, IgG anti-b2GPI–
oxLig-1 independently predicted IMTof B (b ¼ 0.40,
p ¼ 0.01), CC (b ¼ 0.36, p ¼ 0.02) and IC (b ¼ 0.55,
p ¼ 0.003).
Effect of antiphospholipid antibodies on paraoxonase
activity
PON activity in the presence of IS4 was signiﬁcantly
reduced after 3h of incubation at the starting
concentration of 10g/ml compared with the same
concentration of irrelevant human IgG or PBS (p ,
0 . 0 0 1 ) ( F i g u r e4 ) .W B - C A L - 1( t h em u r i n eI g Ga n t i h u -
man b2GPI) and EY2C9 (the human IgM anti-b2GPI)
h a dn oe f f e c ta ta n yc o n c e n t r a t i o no nP O Nn o rd i d
b2GPI and b2GPI–oxLDL complexes at any concen-
tration(Figure5).In dose-dependencyexperimentsIgG
aCL (IS4) signiﬁcantly inhibited PON activity at the
starting concentration of 10g/ml and at 1:2 and 1:4
dilutionscomparedto1:8and1:16dilutions(p , 0.001,
,0.001 and ,0.01, respectively).
Discussion
Oxidation of LDL plays an important role in athero-
sclerosis, as oxLDL may induce vasoconstriction,
expression of adhesion molecules and cellular prolifer-
ation(Kugiyamaetal.1990,Lehretal.1991,Sakaietal.
1994). On the other hand, immunisation of hyperch-
olesterolemic rabbits with oxLDL suppresses athero-
sclerosis (Palinski et al. 1995) therefore an immune
response to oxidised LDL (oxLDL) may modulate
atherogenesis (Horkko et al. 2000). An inverse
relationship between oxLDL and IgG anti–oxLDL
has been noted in the general population, and it was
implied that anti-oxLDL helps to remove oxLDL from
the bloodstream (Shoji et al. 2001). However, data
contrast on this issue. One study described an inverse
andindependentrelationshipbetweenanti-oxLDLtitre
and IMT of carotid arteries in healthy subjects
(Fukumoto et al. 2000), whereas, IgG–oxLDL titre
positively associated with IMT of the CC artery in
another study (Hulthe et al. 2001). That is, both the
antigen and the corresponding antibody seem to have a
relation with IMT. Similar conﬂicting information is
available for SLE, where oxLDL appeared to be related
toarterialthrombosis(Amengualetal.1997)or venous
thrombosis (Hayem et al. 2001) in SLE-related APS,
whereas, more recently oxLDL related to disease
activity (Gomez-Zumaquero et al. 2004).
The approach used in the present study is a step
ahead of the oxLDL/anti-oxLDL system. b2GPI
complexes with oxLDL and more speciﬁcally with
the 7-ketocholesteryl-9-carboxynonanoate (oxLig-1)
moieties from oxLDL and antibodies against the latter
complex, IgG anti-b2GPI–oxLig-1, identiﬁed arterial
disease in SLE related APS (Lopez et al. 2003). The
relation of this antigen/antibody system with IMT of
Figure 3. Relationship between PON activity and IMTof IC (A)
and B (B) in PAPS.
P. R. J. Ames et al. 6carotid arteries or PON has been investigated neither
in PAPS nor in a normal population.
Median plasma levels of the antigen, b2GPI–
oxLDL complexes, were higher in our control
populations and lower in antiphospholipid subjects,
whereas, the antibodies IgG anti-b2GPI–oxLDL and
IgG anti-b2GPI–oxLig-1 were greatest in the PAPS
group, though they did not identify patients with
arterial thrombosis. With regards to PONa we did not
conﬁrm our previous report of low activity in PAPS
(Delgado Alves et al. 2002) probably due to different
control populations bearing different genetic poly-
morphisms that partly govern the enzymatic activity of
PON (Leviev and James 2000). Notwithstanding,
PONa showed several interesting relationships. In the
control group, b2GPI–oxLDL inversely related to
PONa, indicating that as more LDL becomes
oxidised, more oxLDL is buffered by b2GPI. This is
likely due to an age related decrement of the
antioxidant capacity of PON (Milochevitch and Khalil
2001) given the lack of effect of b2GPI–oxLDL on
PONa in our in vitro experiments and the loss of
correlation between b2GPI–oxLDL and IMT of
carotid segments after correction for age. We cannot
discount the possibility that IgG anti-b2GPI–oxLig-1
appears as an attempt to clear b2GPI–oxLDL,
in a fashion similar to that described between
oxLDL and IgG oxLDL in normal subjects (Shoji
et al. 2001). The data of our thrombotic control group
partially replicate those of our normal control group
and altogether they suggest that b2GPI–oxLDL, IgG
anti-b2GPI–oxLig-1 and anti b2GPI–oxLDL might
have a role in vascular ageing in normal people.
The PAPS group shows picture almost specular to
that of the control groups. In fact, PONa negatively
related to IgG b2GPI–oxLig-1, to IgG b2GPI and IgG
aCL, in keeping with our hypothesis that PONa
inhibition participates in APS related vascular damage
(8, 32). Here, we extend this concept, in that elevated
IgG anti-b2GPI–oxLig-1 together with low PONa
were positive and negative correlates of the IMT of
carotidarterysegmentsandbecauseIgGaCLinhibited
PONa in vitro. The latter effect was limited to IS4, the
monoclonal IgG aCL, whereas, WB-CAL-1, the
monoclonal IgG anti-b2GPI was devoid of such effect.
Figure 4. Relationship between IgG anti-b2GPI–oxLig-1 and IMTof CC (A), B (B) and IC in PAPS.
Figure 5. Effect of monoclonal antibodies IS4, WB-CAL-1 and of
b2GPI, b2GPI–oxLDL compared to irrelevant human IgG (at
210min IgG IS4 vs control IgG, p , 0.001).
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PONainSCIDmice,wherenoeffectwasseenforanti-
b2GPI of either isotype (of a different source from the
ones used here (Delgado Alves et al. 2005)). Further
studies are required to elucidate the interaction
between aPL and PON.
With consideration to the small numbers of our
groups, we suggest the following sequence of events. In
normal people, an age related decrease of PONa allows
for oxidation of LDL that is buffered by b2GPI and
eventually an antibody develops to clear this ternary
complex. By contrast, in PAPS, aPL interference with
PONa tilts the oxidant/antioxidant balance towards
enhanced lipid peroxidation (Ames et al. 1998) that in
turn contributes to arterial thickening. Although, this
study was not devised to demonstrating premature
vascular damage in PAPS, it provides further evidence
for PON and IgG anti-b2GPI–oxLig-1 implication in
an atherogenic pathway that may represent a target for
therapeutic intervention.
References
Amengual O, Atsumi T, Khamashta MA, Tinahones F, Hughes
GRV. 1997. Autoantibodies against oxidised low-density
lipoprotein in antiphospholipid syndrome. Br J Rheumatol
369:964–968.
Ames PRJ, Margarita A, Delgado Alves J, Tommasino C,
Iannaccone L, Brancaccio V. 2002. Anticardiolipin antibody
titre and plasma homocysteine level independently predict
intima media thickness of carotid arteries in subjects with
idiopathic antiphospholipid antibodies. Lupus 11:208–214.
Ames PRJ, Margarita A, Sokoll KB, Iannaccone L, Brancaccio V.
2005. Atherosclerosis in primary antiphospholipid syndrome.
Preliminary data. Ann Rheum Dis 64:315–317.
Ames PRJ, Nourooz-Zadeh J, Tommasino C, Alves J, Brancaccio V,
Anggard EE. 1998. Oxidative stress in primary antiphospholipid
syndrome. Thromb Haemos 79:447–449.
Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S,
Linton MF, Raggi P, Stein CM. 2003. Premature coronary-
artery atherosclerosis in systemic lupus erythematosus. N Engl J
Med 349:2407–2415.
Delgado Alves J, Ames PRJ,Donohue S, Stanyer L, Nourooz-Zadeh
J, Ravirajan C, Isenberg DA, Noorouz-Zadeh J. 2002.
Antibodies to high-density lipoprotein and b-2-glycoprotein I
are inversely correlated with paraoxonase activity in systemic
lupus erythematosus and primary antiphospholipid syndrome.
Arthritis Rheum 46:2686–2694.
Delgado Alves J, Mason LJ, Ames Paul RJ, Chen PP, Rauch J,
Levine JS, Subang R, Isenberg DA. 2005. Antiphospholipid
antibodies are associated with enhanced oxidative stress,
decreased plasma nitric oxide and paraoxonase activity in an
experimental mouse mode. Rheumatology, In press.
FukumotoM,ShojiT,EmotoM,Kawagishi T,Okuno Y,Nishizawa
Y. 2000. Antibodies against oxidised LDL and carotid artery
intima-media thickness in a healthy population. Arterioscler
Thromb Vasc Biol 20:703–707.
George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A,
Levkovitz H, Shaish A, Goldberg I, Kopolovic J, Harats D,
Shoenfeld Y. 1998. Induction of early atherosclerosis in LDL-
receptor-deﬁcient mice immunized with b-2-glycoprotein I.
Circulation 98:1108–1115.
Gomez-Zumaquero JM, Tinahones FJ, De Ramon E, Camps M,
Garrido L, Soriguer FJ. 2004. Association of biological markers
of activity of systemic lupus erythematosus with levels of anti-
oxidised low-density lipoprotein antibodies. Rheumatology.
Greaves M, Cohen H, Machin SJ, Mackie I. 2000. Guidelines on
the investigation and management of the antiphospholipid
syndrome. Br J Haematol 109:704–715.
Hashimoto Y, Kawamura M, Ichikawa K, et al. 1992. Antic-
ardiolipin antibodies in NZW £ BXSB F1 mice: A model of
antiphospholipid syndrome. J Immunol 42:1309–1311.
Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T.
1997. Involvement of b 2-glycoprotein I and anticardiolipin
antibodies in oxidatively modiﬁed low-density lipoprotein
uptake by macrophages. Clin Exp Immunol 107:569–573.
Hayem G, Nicaise-Roland P, Palazzo E, de Bandt M, Tubach F,
Weber M, Meyer O. 2001. Anti-oxidised low-density-lipoprotein
(OxLDL) antibodies in systemic lupus erythematosus with and
without antiphospholipid syndrome. Lupus 10:346–351.
Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M. 1991.
Alzola C for the ARIC investigators. Carotid atherosclerosis
measured by B-mode ultrasound in populations: Associations
with cardiovascular risk factor in the ARIC study. Am J
Epidemiol 134:250–256.
Horkko S, Binder CJ, Shaw PX, Chang MK, Silverman G, Palinski
W, Witztum JL. 2000. Immunological responses to oxidised
LDL. Free Radic Biol Med 28:1771–1779.
Hulthe J, Bokemark L, Fagerberg B. 2001. Antibodies to oxidised
LDL in relationto intima-mediathickness in carotidand femoral
arteries in 58-year-old subjectively clinically healthy men.
Arterioscler Thromb Vasc Biol 21:101–107.
Ichikawa K, Khamashta MA, Koike T, et al. 1994. 2-glycoprotein
reactivityon monoclonal anticardiolipin antibodiesfrompatients
with the antiphospholipid syndrome. Arthritis Rheum
37:1453–1461.
Kobayashi K, Kishi M, Atsumi T, Bertolaccini ML, Makino H,
Sakairi N, Yamamoto I, Yasuda T, Khamashta MA, Hughes GR,
Koike T, Voelker DR, Matsuura E. 2003. Circulating oxidised
LDL forms complexeswith b-2-glycoproteinI: Implication as an
atherogenic autoantigen. J Lipid Res 44:716–726.
Kugiyama K, Kerns S, Morrisett J, Roberts R, Henry P. 1990.
Impairment of endothelium-dependent arterial relaxation by
lysolecithin in modiﬁed lipoproteins. Nature 344:160–162.
Lehr H, Hubner C, Nolte D, Finckh B, Biesiegel U, Kohlschutter A,
Messmer K. 1991. Oxidatively modiﬁed human low-density
lipoprotein stimulates leucocyte adherence onto the microvas-
cular endothelium in vitro. Res Exp Med 191:85–90.
Leviev I, James RW. 2000. Promoter polymorphisms of human
paraoxonase PON1 gene and serum paraoxonase activities and
concentrations. Arterioscler Thromb Vasc Biol 20:516–521.
Liu Q, Kobayashi K, Furukawa J, Inagaki J, Sakairi N, Iwado A,
Yasuda T, Koike T, Voelker DR. 2002. Matsuura E V-carboxyl
variants of 7 ketocholesteryl esters are ligands for b-2-
glycoprotein I and mediate antibody-dependent uptake of
oxidised LDL by macrophages. J Lipid Res 43:1486–1495.
Lopez D, Kobayashi K, Merrill JT, Matsuura E, Lopez LR. 2003.
IgG autoantibodies against b-2-glicoprotein I complexed with a
lipid ligand derived from oxidised low-density lipoprotein are
associated with arterial thrombosis in antiphospholipid syn-
drome. Clin Dev Immunol 10:203–211.
Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy
RP, Kuller LH. 1999. Prevalence and risk factors of carotid
plaque in women with systemic lupus erythematosus. Arthritis
Rheum 42:51–60.
Milochevitch C, Khalil A. 2001. Study of the paraoxonase and
platelet-activating factor acetylhydrolase activities with aging.
Prostaglandins Leukot Essent Fatty Acids 65:241–246.
Palinski W, Miller E, Witztum JL. 1995. Immunisation of low-
density lipoprotein (LDL) receptor deﬁcient rabbits with
homologous malondialdehyde-modiﬁed LDL reduces athero-
sclerosis. Proc Nat Acad Sci USA 92:821–825.
P. R. J. Ames et al. 8Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L,
Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB,
Salmon JE. 2003. Prevalence and correlates of accelerated
atherosclerosis in systemic lupus erythematosus. N Engl J Med
349:2399–2406.
Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M,
Shichiri M, Oriuchi S. 1994. Lysophosphatidylcholine plays an
essential role in the mitogenic effect of oxidised low-density
lipoprotein on murine macrophages. J Biol Chem
269:31430–31435.
Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J,
Kanda H, Emoto M, Kawagishi T, Morii H. 2001. Inverse
relationship between circulating oxidised low density lipoprotein
(oxLDL) and anti-oxLDL antibody levels in healthy subjects.
Atherosclerosis 148:171–177.
Wilson WA, Gharavi AE, Koike T, et al. 1999. International
consensus statement on preliminary classiﬁcation criteria for
deﬁnite antiphospholipid syndrome: Report of an international
workshop. Arthritis Rheum 42:1309–1311.
Zhu M, Olee I, Le DT, Roubey RA, Hahn B, Woods Jr, VL, Chen
PP. 1999. Characterization of IgG monoclonal anti-cardiolipi-
n/anti-b2-GPI antibodies from two patients with antipho-
spholipid syndrome reveals three species of antibodies. Br J
Haematol 105:102–109.
Primary antiphospholipid syndrome 9